Vanguard Group’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.83M | Buy |
424,821
+5,654
| +1% | +$50.7K | ﹤0.01% | 3586 |
|
|
2025
Q3 | $16.3M | Buy |
419,167
+20,757
| +5% | +$591K | ﹤0.01% | 2723 |
|
|
2025
Q2 | $9.29M | Buy |
398,410
+342,376
| +611% | +$8.1M | ﹤0.01% | 2943 |
|
|
2025
Q1 | $852K | Hold |
56,034
| – | – | ﹤0.01% | 3761 |
|
|
2024
Q4 | $1.03M | Sell |
56,034
-6,436
| -10% | -$70.1K | ﹤0.01% | 3756 |
|
|
2024
Q3 | $693K | Sell |
62,470
-39
| -0.1% | -$457 | ﹤0.01% | 3885 |
|
|
2024
Q2 | $581K | Sell |
62,509
-6,415
| -9% | -$153K | ﹤0.01% | 3949 |
|
|
2024
Q1 | $2.26M | Sell |
68,924
-4,161
| -6% | -$108K | ﹤0.01% | 3556 |
|
|
2023
Q4 | $1.95M | Buy |
73,085
+906
| +1% | +$37.5K | ﹤0.01% | 3617 |
|
|
2023
Q3 | $4.37M | Buy |
72,179
+124
| +0.2% | +$11.6K | ﹤0.01% | 3309 |
|
|
2023
Q2 | $7.34M | Sell |
72,055
-14,690
| -17% | -$2.02M | ﹤0.01% | 3122 |
|
|
2023
Q1 | $15.3M | Buy |
86,745
+586
| +0.7% | +$196K | ﹤0.01% | 2718 |
|
|
2022
Q4 | $33.3M | Sell |
86,159
-5,726
| -6% | -$2.17M | ﹤0.01% | 2377 |
|
|
2022
Q3 | $31M | Buy |
91,885
+1,117
| +1% | +$405K | ﹤0.01% | 2419 |
|
|
2022
Q2 | $29.8M | Buy |
90,768
+646
| +0.7% | +$227K | ﹤0.01% | 2441 |
|
|
2022
Q1 | $39.4M | Buy |
90,122
+5,879
| +7% | +$2.41M | ﹤0.01% | 2419 |
|
|
2021
Q4 | $36.9M | Buy |
84,243
+607
| +0.7% | +$305K | ﹤0.01% | 2518 |
|
|
2021
Q3 | $46.5M | Buy |
83,636
+7,383
| +10% | +$3.7M | ﹤0.01% | 2403 |
|
|
2021
Q2 | $39.2M | Buy |
76,253
+13,663
| +22% | +$8.66M | ﹤0.01% | 2495 |
|
|
2021
Q1 | $48.9M | Sell |
62,590
-153
| -0.2% | -$105K | ﹤0.01% | 2332 |
|
|
2020
Q4 | $34.2M | Buy |
62,743
+526
| +0.8% | +$276K | ﹤0.01% | 2386 |
|
|
2020
Q3 | $28.5M | Sell |
62,217
-463
| -0.7% | -$269K | ﹤0.01% | 2291 |
|
|
2020
Q2 | $38.6M | Sell |
62,680
-562
| -0.9% | -$310K | ﹤0.01% | 2135 |
|
|
2020
Q1 | $30.1M | Buy |
63,242
+2,921
| +5% | +$1.59M | ﹤0.01% | 2097 |
|
|
2019
Q4 | $35M | Sell |
60,321
-31
| -0.1% | -$21.8K | ﹤0.01% | 2272 |
|
|
2019
Q3 | $39.7M | Buy |
60,352
+10,923
| +22% | +$9.08M | ﹤0.01% | 2184 |
|
|
2019
Q2 | $38.3M | Buy |
49,429
+372
| +0.8% | +$261K | ﹤0.01% | 2237 |
|
|
2019
Q1 | $34.6M | Buy |
49,057
+3,368
| +7% | +$2.02M | ﹤0.01% | 2268 |
|
|
2018
Q4 | $21.4M | Buy |
45,689
+2,596
| +6% | +$1.67M | ﹤0.01% | 2412 |
|
|
2018
Q3 | $37.2M | Buy |
43,093
+8,473
| +24% | +$6.12M | ﹤0.01% | 2297 |
|
|
2018
Q2 | $23.9M | Buy |
34,620
+428
| +1% | +$218K | ﹤0.01% | 2492 |
|
|
2018
Q1 | $15.2M | Buy |
34,192
+376
| +1% | +$182K | ﹤0.01% | 2609 |
|
|
2017
Q4 | $14.9M | Buy |
33,816
+977
| +3% | +$445K | ﹤0.01% | 2630 |
|
|
2017
Q3 | $16.2M | Buy |
32,839
+2,065
| +7% | +$1.03M | ﹤0.01% | 2577 |
|
|
2017
Q2 | $17.1M | Buy |
30,774
+4,562
| +17% | +$2.89M | ﹤0.01% | 2528 |
|
|
2017
Q1 | $17.4M | Buy |
26,212
+4,360
| +20% | +$2.33M | ﹤0.01% | 2497 |
|
|
2016
Q4 | $7.31M | Buy |
21,852
+1,756
| +9% | +$564K | ﹤0.01% | 2882 |
|
|
2016
Q3 | $6.04M | Buy |
20,096
+1,472
| +8% | +$319K | ﹤0.01% | 2911 |
|
|
2016
Q2 | $3.23M | Sell |
18,624
-472
| -2% | -$103K | ﹤0.01% | 3184 |
|
|
2016
Q1 | $4.28M | Buy |
19,096
+845
| +5% | +$252K | ﹤0.01% | 3051 |
|
|
2015
Q4 | $11.1M | Buy |
18,251
+3,316
| +22% | +$1.82M | ﹤0.01% | 2584 |
|
|
2015
Q3 | $7.68M | Buy |
14,935
+7,007
| +88% | +$4.69M | ﹤0.01% | 2742 |
|
|
2015
Q2 | $3.47M | Buy |
7,928
+1,490
| +23% | +$576K | ﹤0.01% | 3182 |
|
|
2015
Q1 | $2.33M | Buy |
6,438
+1,574
| +32% | +$596K | ﹤0.01% | 3337 |
|
|
2014
Q4 | $1.75M | Sell |
4,864
-5
| -0.1% | -$1.61K | ﹤0.01% | 3335 |
|
|
2014
Q3 | $1.47M | Sell |
4,869
-1,850
| -28% | -$760K | ﹤0.01% | 3381 |
|
|
2014
Q2 | $4.12M | Buy |
6,719
+4,051
| +152% | +$2.18M | ﹤0.01% | 2943 |
|
|
2014
Q1 | $1.79M | Buy |
+2,668
| New | +$1.58M | ﹤0.01% | 3272 |
|
Other funds holding TVRD
SPC
AFG
SAM
DWAM
Vanguard Group's TVRD Position: Q4 2025 in Review
Vanguard Group increased its Tvardi Therapeutics (TVRD) stake by 1.3% in Q4 2025, buying an estimated $50.7K and bringing the position to 424,821 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3586.
Vanguard Group first reported a position in TVRD in Q1 2014 and has held it in 48 quarters since. The position peaked at $48.9M in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q4 2025.
- Vanguard Group held 424,821 shares of Tvardi Therapeutics worth $1.83M as of Q4 2025.
- Vanguard Group bought 5,654 Tvardi Therapeutics shares in Q4 2025, an estimated $50.7K.
- Tvardi Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3586 holding.
- Vanguard Group first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 48 quarters since.
- Vanguard Group's Tvardi Therapeutics position peaked at $48.9M in Q1 2021.
- 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.